We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Analysis Procedure Determines a Child's Sex in Early Pregnancy

By Biotechdaily staff writers
Posted on 03 Jun 2008
A new genetic test identifies the sex of the fetus and uncovers genetic diseases from the eighth week of pregnancy by analyzing the fetal DNA found in the blood plasma of the expectant mother.

Researchers from the University of Granada (UGR, Spain) , in collaboration with the maternity hospital Virgen de las Nieves (Granada, Spain) developed the new technique, which is based on the fact that during pregnancy, between 3.4 and 6.2% of the total DNA free in maternal plasma has a fetal origin. More...
Therefore, a simple peripheral blood sample is enough for the test, which opens new possibilities in the field of non-invasive prenatal diagnosis. All the expectant mother needs to carry out the test is supply a 3-ml blood sample with an anticoagulant, which is then sent to the testing laboratory, a spin-off of the University of Granada and Virgen de las Nieves named Lorgen (Granada, Spain). Test results are returned within 48 hours. Although the test can be carried out from the sixth week of pregnancy, the reliability of the technique is much higher from the eighth. The researchers conducted a clinical trial of the new method in 120 pregnant women, and found that the test's effectiveness rate was above 98%.

The new process has many medical applications, especially in the diagnosis of monogenic diseases related to X chromosome, such as hemophilia or Duchenne muscular dystrophy. In these cases, the possibility of determining the sex of the baby as soon as possible avoids invasive prenatal diagnosis procedures such as amniocentesis, chorionic villus biopsy, or cordcentesis, which involve a potential danger to the life of the fetus.

"The ‘golden dream' is to be able to detect and diagnose Down syndrome from fetal DNA present in the mother's blood,” said Sebastián Manzanares, M.D., director of the fetal medicine unit of the Virgen de las Nieves University Hospital. "That would be the end of the process, but before that we would be able to study many more genes. For the moment, we need to continue with amniocentesis.”


Related Links:
Lorgen
University of Granada
Virgen de las Nieves maternity Hospital

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.